CN117412747A - 用于治疗激越的方法和组合物 - Google Patents

用于治疗激越的方法和组合物 Download PDF

Info

Publication number
CN117412747A
CN117412747A CN202280027623.0A CN202280027623A CN117412747A CN 117412747 A CN117412747 A CN 117412747A CN 202280027623 A CN202280027623 A CN 202280027623A CN 117412747 A CN117412747 A CN 117412747A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
dosage form
subject
dexmedetomidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280027623.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·K·杜尔
V·卡库马努
S·塞斯
D·C·汉利
M·德维沃
F·波斯玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxcel Therapeutics Inc
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of CN117412747A publication Critical patent/CN117412747A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280027623.0A 2021-02-26 2022-02-25 用于治疗激越的方法和组合物 Pending CN117412747A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154281P 2021-02-26 2021-02-26
US63/154,281 2021-02-26
PCT/US2022/017963 WO2022183029A1 (en) 2021-02-26 2022-02-25 Methods and compositions for treating agitation

Publications (1)

Publication Number Publication Date
CN117412747A true CN117412747A (zh) 2024-01-16

Family

ID=83048476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280027623.0A Pending CN117412747A (zh) 2021-02-26 2022-02-25 用于治疗激越的方法和组合物

Country Status (7)

Country Link
US (2) US20240139169A1 (cg-RX-API-DMAC7.html)
EP (1) EP4297871A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024507991A (cg-RX-API-DMAC7.html)
CN (1) CN117412747A (cg-RX-API-DMAC7.html)
CA (1) CA3208828A1 (cg-RX-API-DMAC7.html)
TW (1) TW202302094A (cg-RX-API-DMAC7.html)
WO (1) WO2022183029A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
AU2020407163A1 (en) * 2019-12-16 2022-07-21 Minute Molecular Diagnostics, Inc. Lyophilized reagents
EP4580619A1 (en) * 2022-08-31 2025-07-09 BioXcel Therapeutics, Inc. Methods and compositions for treating acute stress disorder
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2024211911A1 (en) * 2023-04-07 2024-10-10 Oaktree Fund Administration, Llc Methods for treating depressive states
WO2024263973A1 (en) * 2023-06-23 2024-12-26 Bioxcel Therapeutics, Inc. Dexmedetomidine treatment regimens

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) * 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
US20070117835A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
US20100152108A1 (en) * 2006-10-27 2010-06-17 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2243468A1 (en) * 2009-04-17 2010-10-27 Sanovel Ilac Sanayi ve Ticaret A.S. Orally Disintegrating Dimebolin Compositions
WO2011039686A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
US20110172262A1 (en) * 2008-09-15 2011-07-14 Biovista, Inc. Compositions and methods for treating epilepsy
US20110269777A1 (en) * 2007-08-01 2011-11-03 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
WO2013114400A2 (en) * 2012-01-20 2013-08-08 Rubicon Research Private Limited Compressed pharmaceutical compositions of atypical antipsychotics
EP2774991A1 (en) * 2013-03-06 2014-09-10 Life Science Inkubator Betriebs GmbH & Co. KG Drug delivery system for use in the treatment or diagnosis of neurological disorders
CN104530413A (zh) * 2014-10-01 2015-04-22 厦门赛诺邦格生物科技有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
WO2016061554A1 (en) * 2014-10-16 2016-04-21 Bioxcel Corporation Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof
US20170239221A1 (en) * 2014-10-15 2017-08-24 Bioxcel Corporation Prevention or treatment of sleep disorders using dexmedetomidine formulation
CN110337290A (zh) * 2016-12-31 2019-10-15 比奥克斯塞尔医疗股份有限公司 舌下右旋美托咪啶用于治疗激越的用途
WO2020006092A1 (en) * 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
WO2021016112A2 (en) * 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN116615243A (zh) * 2020-10-08 2023-08-18 比奥克斯塞尔医疗股份有限公司 使用右美托咪啶盐酸盐治疗躁郁症和精神病

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2200610T3 (cg-RX-API-DMAC7.html) * 2007-09-21 2018-06-09
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
JP6013364B2 (ja) * 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルapiローディングプロドラッグ

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) * 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
US20070117835A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100152108A1 (en) * 2006-10-27 2010-06-17 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
US20110269777A1 (en) * 2007-08-01 2011-11-03 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
US20110172262A1 (en) * 2008-09-15 2011-07-14 Biovista, Inc. Compositions and methods for treating epilepsy
EP2243468A1 (en) * 2009-04-17 2010-10-27 Sanovel Ilac Sanayi ve Ticaret A.S. Orally Disintegrating Dimebolin Compositions
WO2011039686A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
WO2013114400A2 (en) * 2012-01-20 2013-08-08 Rubicon Research Private Limited Compressed pharmaceutical compositions of atypical antipsychotics
EP2774991A1 (en) * 2013-03-06 2014-09-10 Life Science Inkubator Betriebs GmbH & Co. KG Drug delivery system for use in the treatment or diagnosis of neurological disorders
CN104530413A (zh) * 2014-10-01 2015-04-22 厦门赛诺邦格生物科技有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
US20170239221A1 (en) * 2014-10-15 2017-08-24 Bioxcel Corporation Prevention or treatment of sleep disorders using dexmedetomidine formulation
WO2016061554A1 (en) * 2014-10-16 2016-04-21 Bioxcel Corporation Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof
CN110337290A (zh) * 2016-12-31 2019-10-15 比奥克斯塞尔医疗股份有限公司 舌下右旋美托咪啶用于治疗激越的用途
WO2020006092A1 (en) * 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
WO2021016112A2 (en) * 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN116615243A (zh) * 2020-10-08 2023-08-18 比奥克斯塞尔医疗股份有限公司 使用右美托咪啶盐酸盐治疗躁郁症和精神病

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSSI G,等: "Management of Agitation in Huntington’s Disease: A Review of the Literature", CUREUS, vol. 12, no. 08, 14 August 2020 (2020-08-14) *

Also Published As

Publication number Publication date
US20250228833A1 (en) 2025-07-17
JP2024507991A (ja) 2024-02-21
EP4297871A4 (en) 2025-01-01
WO2022183029A1 (en) 2022-09-01
EP4297871A1 (en) 2024-01-03
CA3208828A1 (en) 2022-09-01
TW202302094A (zh) 2023-01-16
US20240139169A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
US20250228833A1 (en) Methods and compositions for treating agitation
JP7008153B2 (ja) 激越の治療のための舌下デクスメデトミジンの使用
Fu et al. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies
JP2013539790A (ja) メマンチンを含む鎮咳組成物
MXPA06000529A (es) Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
JP2010248106A (ja) フィルムコーティング錠
JP2023545372A (ja) デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療
US20130274342A1 (en) Compositions and methods for treating cough
CN1173701C (zh) 含有米氮平的口内崩解组合物
KR20240089377A (ko) 자폐 스펙트럼 장애를 갖는 대상체를 치료하기 위한 방법 및 생성물
JP6061924B2 (ja) 口腔内分散性製剤
US20090269393A1 (en) Chewable Bilayer Tablet Formulation
TW202416979A (zh) 用於治療急性壓力症之方法及組合物
JP2019515045A (ja) 甲状腺ホルモン又はそのアナログを提供する組成物及び方法
Nagpal et al. Patent innovations in fast dissolving/disintegrating dosage forms
WO2025128666A1 (en) Combination of latrepirdine and a pharmacokinetic stabilizer
PHARMACEUTICS FORMULATION AND CHARACTERIZATION OF RIZATRIPTAN BENZOATE SUBLINGUAL TABLET WITH VARIOUS PERMEATION ENHANCERS
HK40014031A (en) Use of sublingual dexmedetomidine for the treatment of agitation
HK1242579A1 (en) Oral therapeutic compound delivery system
JP2010100550A (ja) 医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination